Researchers aimed to assess the impact of aspirin on incidence of serious GI bleeding in an older population, identify risk factors, and calculate absolute bleeding risk according to age and presence of risk factors.
Ticagrelor and prasugrel, the newer generation of P2Y12-inhibiting antiplatelet agents, were found to be associated with fewer gastrointestinal bleeding events the first year after percutaneous coronary intervention compared with clopidogrel.
In patients with acute lower gastrointestinal bleeding (ALGIB), colonoscopies performed within 24 hours after hospital admission did not reduce rebleeding or increase stigmata of recent hemorrhage (SRH) compared with colonoscopies performed between 24 to 96 hours after hospital admission.
Patients who restart their blood thinners after a gastrointestinal bleed have a lower risk for dying within the next two years even though they have a higher risk for recurrent gastrointestinal bleeding.
Patients with bleeding gastrointestinal angiodysplasias who are receiving antithrombotic therapy have a lower probability of rebleeding when treated with hemoclips (in combination or as monotherapy), compared with the use of argon plasma photocoagulation.
Use of an H2RA may reduce the risk for GI bleeding in high-risk newborns and use of an H2RA or PPI may reduce the duration of upper GI bleeding and incidence of continued bleeding in newborns with this condition.